Clinical Trial Update: TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating TAS-102 (trifluridine/tipiracil) with concurrent radiation for untreated resectable stage II-III rectal cancer; the study is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8 | Phase 1 | Status: ACTIVE_NOT_RECRUITING